Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.
![Thumbnail](/bitstream/handle/10576/32084/s41467-022-30895-3.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Date
2022-06-02Author
Chemaitelly, HiamAyoub, Houssein H
AlMukdad, Sawsan
Coyle, Peter
Tang, Patrick
Yassine, Hadi M
Al-Khatib, Hebah A
Smatti, Maria K
Hasan, Mohammad R
Al-Kanaani, Zaina
Al-Kuwari, Einas
Jeremijenko, Andrew
Kaleeckal, Anvar Hassan
Latif, Ali Nizar
Shaik, Riyazuddin Mohammad
Abdul-Rahim, Hanan F
Nasrallah, Gheyath K
Al-Kuwari, Mohamed Ghaith
Butt, Adeel A
Al-Romaihi, Hamad Eid
Al-Thani, Mohamed H
Al-Khal, Abdullatif
Bertollini, Roberto
Abu-Raddad, Laith J
...show more authors ...show less authors
Metadata
Show full item recordAbstract
SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 vaccines against BA.1 and BA.2 infections in Qatar. BNT162b2 effectiveness was highest at 46.6% (95% CI: 33.4-57.2%) against symptomatic BA.1 and at 51.7% (95% CI: 43.2-58.9%) against symptomatic BA.2 infections in the first three months after the second dose, but declined to ~10% or below thereafter. Effectiveness rebounded to 59.9% (95% CI: 51.2-67.0%) and 43.7% (95% CI: 36.5-50.0%), respectively, in the first month after the booster dose, before declining again. Effectiveness against COVID-19 hospitalization and death was 70-80% after the second dose and >90% after the booster dose. mRNA-1273 vaccine protection showed similar patterns. mRNA vaccines provide comparable, moderate, and short-lived protection against symptomatic BA.1 and BA.2 Omicron infections, but strong and durable protection against COVID-19 hospitalization and death.
Collections
- Biomedical Research Center Research [709 items ]
- Biomedical Sciences [692 items ]
- COVID-19 Research [799 items ]
- Mathematics, Statistics & Physics [722 items ]
- Public Health [401 items ]